Search - tctmd.com

Displaying 1 - 20 of 23

Sort: Relevancy | Date

News Daily News

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Michael O'Riordan

August 06, 2025

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

News Daily News

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

Michael O'Riordan

July 31, 2025

News Conference News SCCT 2025

Less Plaque With Intensive Medical Therapy vs Usual Care in INOCA: WARRIOR

Yael L. Maxwell

July 28, 2025

News Daily News

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Michael O'Riordan

July 14, 2025

News Daily News

Novel Calcium Score Accounting for Density and Location Ups MACE Prediction

Yael L. Maxwell

July 11, 2025

News Daily News

CV Risk Modest for Most Cancer Survivors in Large Danish Registry

L.A. McKeown

June 17, 2025

News Daily News

GLP-1s Reduce Limb and Cardiac Events in Peripheral Artery Disease

L.A. McKeown

June 12, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Conference News European Congress on Obesity 2025

Obesity-Related Cancer Rates No Different With GLP-1s vs Bariatric Surgery

Michael O'Riordan

May 14, 2025

News Conference News European Congress on Obesity 2025

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

Michael O'Riordan

May 14, 2025

News Conference News EAS 2025

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Yael L. Maxwell

May 08, 2025

News Daily News

Knowledge of Genetic Risk for CAD Bolsters Prevention, Reduces MACE

Caitlin E. Cox

April 23, 2025

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

News Daily News

Cannabis Use Again Tied to Increased CVD Risk in Young People

L.A. McKeown

March 19, 2025

News Daily News

Newer Weight-Loss Drugs Not Cost-effective at Current Prices

Michael O'Riordan

March 18, 2025

News Daily News

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

Michael O'Riordan

March 06, 2025

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2025

Shelley Wood

January 31, 2025

Advertisement

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

Less Plaque With Intensive Medical Therapy vs Usual Care in INOCA: WARRIOR

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Novel Calcium Score Accounting for Density and Location Ups MACE Prediction

CV Risk Modest for Most Cancer Survivors in Large Danish Registry

GLP-1s Reduce Limb and Cardiac Events in Peripheral Artery Disease

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Obesity-Related Cancer Rates No Different With GLP-1s vs Bariatric Surgery

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Knowledge of Genetic Risk for CAD Bolsters Prevention, Reduces MACE

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Cannabis Use Again Tied to Increased CVD Risk in Young People

Newer Weight-Loss Drugs Not Cost-effective at Current Prices

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

TCTMD’s Top 10 Most Popular Stories for January 2025

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content